Travere’s Filspari Poised to Dominate IgA Nephropathy Market

Travere Therapeutics’ innovative drug Filspari is showing significant promise in the treatment of IgA nephropathy, even though it has not yet received full regulatory approval. Filspari, an endothelin and angiotensin II receptor antagonist, received accelerated approval from the FDA in February 2023 and has since been making notable progress in managing this rare autoimmune disease.

IgA nephropathy, also known as Berger's disease, is characterized by the accumulation of immunoglobulin A in the kidneys, which leads to blood and protein in the urine. This condition affects about 60,000 individuals in the United States. The National Kidney Foundation highlights four primary classes of drugs used to treat IgA nephropathy: corticosteroids, immunotherapies, ACE inhibitors, and angiotensin II blockers. While corticosteroids and immunotherapies work by suppressing the immune system, ACE inhibitors and angiotensin II blockers reduce the activity of angiotensin in the body, lowering blood pressure and proteinuria through the renin-angiotensin-aldosterone system.

Filspari's clinical efficacy offers compelling reasons for healthcare providers to consider it over traditional treatments. Immunotherapies like cyclophosphamide combined with prednisone can cause severe side effects, including drug-induced hepatitis and systemic infections. In contrast, Filspari is recognized as the first non-immunosuppressive therapy to reduce proteinuria in IgA nephropathy. The side effects associated with Filspari, such as peripheral edema, hypotension, dizziness, hyperkalemia, and anemia, are generally easier to manage than those of immunotherapies.

Travere reports that traditional ACE inhibitors or angiotensin receptor blockers, which lack endothelin activity, have only been able to delay the progression to end-stage renal disease by an average of 7.9 years. However, angiotensin II receptor antagonists with endothelin inhibition, like irbesartan or Filspari, have shown more favorable outcomes. Irbesartan can delay end-stage renal disease by 11.1 years on average, while Filspari can extend this period to 15.6 years. Irbesartan, marketed under the brand name Avapro, is similar to Filspari and is approved for hypertension and diabetic nephropathy treatment.

Given the superior long-term management provided by drugs with endothelin-inhibiting activity, such as Filspari, they are poised to become the preferred treatment option for IgA nephropathy. Although Calliditas Therapeutics’ Tarpeyo (budesonide) received full approval in December 2023, it focuses on the source of IgA antibody production rather than the root cause of the disease and can lead to infections if used long-term.

Travere is not only looking to establish Filspari as the first-line treatment for IgA nephropathy but also to expand its indications to other renal diseases like focal segmental glomerulosclerosis. The company is exploring the potential of using Filspari in earlier stages of the disease to enhance kidney protection.

Future clinical trials may investigate the combination of Filspari with Tarpeyo, as Filspari cannot be combined with other angiotensin receptor blockers. This combination could provide a comprehensive treatment approach for IgA nephropathy. With Filspari, Travere is strategically positioned to broaden its impact on rare diseases in the coming years.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!